Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
4.350
-0.450 (-9.38%)
At close: Feb 21, 2025, 4:00 PM
4.460
+0.110 (2.53%)
After-hours: Feb 21, 2025, 7:50 PM EST
Windtree Therapeutics Employees
Windtree Therapeutics had 20 employees as of December 31, 2022. The number of employees decreased by 13 or -39.39% compared to the previous year.
Employees
20
Change (1Y)
-13
Growth (1Y)
-39.39%
Revenue / Employee
n/a
Profits / Employee
-$535,450
Market Cap
782.11K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
WINT News
- 5 weeks ago - Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - GlobeNewsWire
- 5 weeks ago - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - GlobeNewsWire
- 2 months ago - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia - GlobeNewsWire
- 2 months ago - Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction - GlobeNewsWire
- 3 months ago - Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - GlobeNewsWire
- 4 months ago - Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewsWire
- 4 months ago - Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - GlobeNewsWire
- 5 months ago - Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock - GlobeNewsWire